Ferulic Acid

The continuous rise in the prevalence of chronic diseases such as cardiovascular and cerebrovascular diseases and chronic inflammation has promoted anti-inflammatory and antioxidant active ingredients of natural origin to become a research hotspot in clinical and consumer fields. Ferulic acid is a cinnamic acid derivative, which can reduce the production of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the activities of cyclooxygenase and lipoxygenase, meanwhile scavenge oxygen free radicals and inhibit platelet aggregation, and has multiple effects of anti-inflammation, anti-oxidation, anti-thrombosis and immune regulation. At the clinical level, ferulic acid can be used for the adjuvant treatment of vascular diseases such as coronary heart disease, cerebrovascular disease and vasculitis, and can also be added as a functional ingredient to skin care and dietary supplement products, applicable to populations covering patients with chronic cardiovascular and cerebrovascular diseases, people susceptible to inflammation and healthy consumer groups.

At present, the global ferulic acid market size is about USD 320 million, and the compound annual growth rate from 2023 to 2028 is expected to reach 6.8%. The core growth drivers on the demand side come from the two downstream fields of medicine and cosmetics: on the medicinal side, with the optimization of the drug structure for cardiovascular and cerebrovascular diseases, the clinical usage of ferulic acid compound preparations has increased year by year; on the consumer side, the rising demand for natural active ingredients has driven the continuous increase of the addition proportion of ferulic acid in skin care products and dietary supplements. In terms of competitive landscape, domestic enterprises account for nearly 70% of the global production capacity, which are mainly distributed in Sichuan, Jiangsu and other regions. The production process is mainly plant extraction, and leading enterprises have realized mass production by synthetic method, with significant cost advantages. In addition to supplying the domestic market, a large number of products are exported to Europe, America and Southeast Asia.

Ferulic acid was first promoted for the development of medicinal preparations by Japan's Tsumura & Co., with the original trade name "Ferula", and the core compound patent expired globally in 1989. At present, the mainstream medicinal dosage forms on the market include tablets (10mg, 20mg), injections (2ml:50mg) and granules. Among them, 20mg tablets and 50mg injections have been included in the FDA Reference Listed Drug Catalog, and are also included in the second volume of the Chinese Pharmacopoeia 2025 Edition. In the domestic medicinal field, 12 enterprises have obtained A status for their ferulic acid API through CDE registration, and nearly 30 ferulic acid preparations and sodium ferulate compound preparations have been approved for marketing, with a relatively mature supply system. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full range of ferulic acid impurity reference standards, which fully cover various impurities generated during the synthesis process and degradation pathways. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA. Most categories support spot supply, and orders placed before 16:00 can be shipped on the same day, which can fully meet the use needs of pharmaceutical enterprises in different scenarios such as R&D, quality research and registration declaration.